Jan van de Winkel
Prof. Dr. Jan van de Winkel is founder and CEO Genmab. With more than 25 years of experience in the therapeutic antibody industry, Jan van de Winkel has played a crucial role in translating cutting-edge science into life-changing medicines.
He is the author of more than 300 scientific publications and is responsible for more than 150 patents and patent applications.
Dr. van de Winkel is professor of immunotherapy at Utrecht University and also holds Masters and PhD degrees from Radboud University.
Jan van de Winkel will give the Utrecht Science Lecture on Friday, Sept. 26.